This promotional information is intended for healthcare professionals based
in the UK.
If you are not a healthcare professional in the UK, click here.
For Prescribing and Adverse Event reporting information, click here.

ELIQUIS® (apixaban) is indicated for prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA), age ≥75 years, hypertension, diabetes mellitus, symptomatic heart failure (NYHA Class ≥II); treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults; and, prevention of venous thromboembolic events (VTE) in patients who have undergone elective hip or knee replacement surgery.


Explore ELIQUIS® for your
patients with DVT / PE

AMPLIFY Clinical Trial

ELIQUIS demonstrated comparable efficacy with a significant reduction in the risk of major bleeding vs. enoxaparin / warfarin in the treatment of DVT / PE1

AMPLIFY-EXT Clinical Trial

ELIQUIS 2.5 mg BD demonstrated superior efficacy vs. placebo, with no statistically significant increase in the rates of both major and major / CRNM bleeding vs. placebo in patients receiving extended treatment for the prevention of recurrent DVT / PE2

Treatment Guidelines

ELIQUIS is recommended by NICE as a treatment option for confirmed proximal DVT or PE3

Real-World Data

In AMPLIFY, ELIQUIS demonstrated comparable efficacy with a superior major bleeding profile vs. enoxaparin / warfarin; this is complemented by RWD1,4

FOOTNOTES

BD = Twice Daily   CRNM = Clinically Relevant Non-Major   DVT = Deep Vein Thrombosis   NICE = National Institute for Health and Care Excellence   
PE = Pulmonary Embolism   RWD = Real-World Data

REFERENCES

  1. Agnelli G et al. N Engl J Med 2013; 369: 799–808.
  2. Agnelli G et al. N Engl J Med 2013; 368: 699–708.
  3. NICE Guideline NG158. Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. March 2020.
  4. Weycker D et al. Thromb Haemost 2018; 118: 1951–1961.